1. Home
  2. SILC vs CRDL Comparison

SILC vs CRDL Comparison

Compare SILC & CRDL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Silicom Ltd

SILC

Silicom Ltd

HOLD

Current Price

$20.79

Market Cap

110.7M

Sector

Technology

ML Signal

HOLD

Logo Cardiol Therapeutics Inc.

CRDL

Cardiol Therapeutics Inc.

HOLD

Current Price

$1.25

Market Cap

97.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SILC
CRDL
Founded
1987
2017
Country
Israel
Canada
Employees
N/A
N/A
Industry
Computer Manufacturing
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
110.7M
97.3M
IPO Year
2002
2017

Fundamental Metrics

Financial Performance
Metric
SILC
CRDL
Price
$20.79
$1.25
Analyst Decision
Hold
Strong Buy
Analyst Count
1
2
Target Price
N/A
$9.00
AVG Volume (30 Days)
45.8K
569.4K
Earning Date
04-27-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$17.17
N/A
Revenue Next Year
$12.28
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$12.44
$0.77
52 Week High
$23.10
$1.59

Technical Indicators

Market Signals
Indicator
SILC
CRDL
Relative Strength Index (RSI) 57.04 69.76
Support Level $17.75 $0.94
Resistance Level $20.96 $1.40
Average True Range (ATR) 1.24 0.08
MACD 0.19 0.02
Stochastic Oscillator 58.14 93.29

Price Performance

Historical Comparison
SILC
CRDL

About SILC Silicom Ltd

Silicom Ltd designs and manufactures networking and data infrastructure solutions for various servers, server-based systems, and communications devices. Its product categories consist of Server Adapters, Edge Networking Solutions, FPGA-Based Cards, x86 Open Appliances, Bypass Switches, and TAPs. Geographically, it derives a majority of its revenue from North America and also has a presence in Europe and Asia-Pacific.

About CRDL Cardiol Therapeutics Inc.

Cardiol Therapeutics Inc is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart diseases. The company's main product candidate, CardiolRx, is a pharmaceutically manufactured oral cannabidiol formulation that is being clinically developed for use in heart diseases. Cardiol has received Investigational New Drug Application authorization from the United States Food and Drug Administration to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart which are a Phase II multi-national trial, the ARCHER trial, in acute myocarditis; and a Phase II multi-center open-label pilot study in recurrent pericarditis.

Share on Social Networks: